Therapeutic angiogenesis in cardiovascular disease aims at improving myocardial function by increasing blood flow to ischemic myocardium that is not amenable to traditional forms of revascularization. Preclinical data have provided proof of the concept that angiogenic growth factors such as fibroblast growth factor 2 (FGF-2) and vascular endothelium growth factor (VEGF) may indeed improve myocardial flow and function when administered in ways that ensure prolonged tissue exposure to these short-lived molecules. Although other cytokines have been shown to enhance angiogenesis in vivo, FGF-2 and VEGF have been most widely studied and may serve as prototype proangiogenic drugs. Currently, several delivery techniques that are clinically applicable are being studied with respect to tissue distribution and retention as well as angiogenic efficacy of FGF-2 and VEGF. Although tissue distribution and retention of FGF-2 after intramyocardial injection compares favorably with other routes of administration, efficacy studies are not yet conclusive. At the same time, different protein-and gene-based formulations are being investigated. Arguments for and against protein and gene therapy are presented, showing that protein-based therapy seems to have advantages over gene therapy at the present time, although continuous efforts should be made to increase the tissue exposure time after a single administration of protein. While delivery systems and growth factor formulations are being improved, double-blind, placebo-controlled trials designed with existing animal data in mind, are needed to firmly establish the utility of therapeutic angiogenesis in cardiovascular disease.
Introduction
therapy. Furthermore, full functional recovery of the ischemic myocardium may not be achieved if revasculariCurrent treatment options for patients with advanced zation is delayed [6] . Preliminary clinical experience with ischemic heart disease include medical therapy or coronary therapeutic angiogenesis suggests that this new treatment revascularization by percutaneous coronary angioplasty may provide additional blood flow to underperfused and (PTCA) or coronary bypass surgery (CABG) [1] [2] [3] [4] . Howincompletely revascularized areas and thus be valuable in ever, a significant number of these patients are not the management of these patients [7] [8] [9] [10] [11] . candidates for standard revascularization procedures or have incomplete revascularization with these procedures [1, 5] . For example, in patients with 2-and 3-vessel 2. Biology of cardiac angiogenesis in adult tissues disease, complete revascularization of hemodynamically significant stenoses was successful in 23 and 9% of cases,
To evaluate different treatment strategies it is important respectively [5] . As a result, many of these patients have to understand the basic pathophysiology of blood vessel residual symptoms of myocardial ischemia despite medical formation in adult tissues. Three different processes may contribute to the growth of new blood vessels: vasculogenesis, arteriogenesis and angiogenesis [12] [13] [14] .
from pluripotent endothelial stem cells [15] , which in the interleukin 1a (IL-1a), substance P [35], insulin-like course of embryonic development, results in formation of growth factor 1 (IGF-1) [36] , CXC chemokines [37], primitive vascular plexus, and is followed by recruitment tumor necrosis factor a (TNF-a) [38] , proline / arginine of other vascular cell types to complete the process of rich peptide 39 (PR 39) [39] and various matrix proteases vessel formation. Preliminary evidence suggests that vas- [14, 40] are actively involved in adult angiogenesis. Inculogenesis may play a role in new vessel formation in flammatory cells such as macrophages most likely propmature adult tissues [16] [17] [18] but the significance and agate the angiogenic response by virtue of their capacity to frequency of this event has not been established.
produce and release angiogenic factors and matrix degradAngiogenesis is the process responsible for formation of ing enzymes [38, 41, 42] . Ineffective inflammatory renew vessels lacking developed media that are thought to sponses, due to genetic make-up [43] , pathophysiological arise, in mature tissues, from postcapillary venules [12] .
processes or pharmacotherapy, may adversely affect the Examples of angiogenesis include capillary proliferation in ability to induce new vessel growth [34, 44] . the healing wound or along the border of myocardial Newly formed vessels, whether formed by natural infarction.
processes or due to therapeutic application of growth Arteriogenesis refers to the appearance of new arteries factors, are typically of capillary or small arteriolar size possessing fully developed tunica media [19] . This is a (10-200 mm) and may or may not possess tunica media poorly understood process that may involve maturation of [45] [46] [47] . The maturation of vessels into multilayer strucpreexisting collaterals or may reflect de novo formation of tures may actually be important for their persistence. mature vessels. Examples of arteriogenesis include formaNeovascularization and subsequent regression of newly tion of angiographically visible collaterals in patients with formed vessels has been observed after single stimuli such advanced obstructive coronary or peripheral vascular disas the mast cell secretagogue 48 / 80 [48] and in tumor ease. All vascular cell types including smooth muscle cells vessels [49] . Whether regression also occurs in growth and pericytes are involved.
factor-induced angiogenesis in the heart or peripheral The occurrence of both angiogenesis and arteriogenesis vasculature and what is required to prevent it, is still has been conclusively demonstrated in a variety of animal unknown. models [20, 21] as well as in patients with coronary disease
Candidates for pharmacological stimulation of therapeu- [22] [23] [24] . Although related, arteriogenesis and angiogenesis tic angiogenesis in cardiac or peripheral limb ischemia may be differentially regulated. Arteriogenesis generally include angiogenic cytokines such as fibroblast growth occurs proximal from the ischemic territory where hemofactors (FGF) [50] , vascular endothelial growth factors dynamic (e.g. shear stress) or hematologic (prothrombotic) (VEGF) [51] , hepatocyte growth / scatter factor (HGF / SF) changes dominate [25] , whereas true angiogenesis is [52] , CXC chemokines such as interleukin 8 (IL-8) [53] primarily driven by hypoxia or tissue ischemia [26, 27] . and monocyte chemoattractant protein 1 (MCP-1) [54] , These general considerations notwithstanding, the differgrowth factors involved in maturation of the vascular tree ences in molecular responses controlling angiogenesis and such as angiopoietins [55] [56] [57] and platelet derived growth arteriogenesis are poorly understood. The occurrence of factor (PDGF) [58, 59] , and transcription factors that tissue ischemia is thought to increase cellular levels of stimulate expression of angiogenic cytokines and their hypoxia-induced factor (HIF)-1a protein that in turn receptors such as HIF1a [60] . upregulates expression of vascular endothelium growth factor (VEGF) and its receptors [28, 29] , leading to increased capillary density in the ischemic regions of the 3. Protein versus gene therapy heart. However, the ability to respond to a hypoxic stimulus may also play an important role in arteriogenic Theoretically, therapeutic angiogenesis can be achieved response. A recent retrospective study documented higher by employing either growth factor proteins or by introincidence of HIF-1a response to hypoxia in monocytes of ducing genes encoding these proteins [61] . Sustained local patients with advanced coronary disease and angiographiproduction and release of growth factors through gene cally visible coronary collaterals (arteriogenesis) compared therapy can overcome the inherent instability of angiogenic to patients who had no or minimal collaterals [30] . In proteins (Table 1 ) [62] [63] [64] and may therefore be preferred. addition, patients with unstable angina frequently demonHowever, although prolonged presence of growth factors strate elevated levels of fibroblast growth factor 2 (FGF-2) may be beneficial, there is no conclusive evidence to in the serum [31] and the pericardial fluid [32] . The support this hypothesis. In fact, preliminary evidence contribution of FGF-2 to the arteriogenic or angiogenic suggests that prolonged local production of potent growth response however, has not been addressed in these studies. [19, 33, 34] . A number of inflammatory mediators such as longer-term angiogenic factor exposure depends on effec- increased from hours to days by a single amino acid (proliferating vs. non-proliferating), and duration and mutation [74] . Furthermore, extended tissue exposure to extent of transgene expression. Plasmid DNA and early the growth factors can be accomplished by a variety of generation adenoviral vectors mediate rather short-term slow release formulations (e.g. heparin-alginate beads) (days to weeks) duration expression, while other viral [75] . At the same time, the major advantage of the protein vectors (e.g. retroviral, lentiviral, AAV) can result in a very therapy approach lies in precise knowledge of delivered long (months) duration of expression. The limited duration dose, the ability to combine several proteins into a single of transgene expression (|1-2 weeks) achieved in the therapeutic formulation and a relatively well understood heart with first generation adenovirus vectors makes them safety profile [61] . In the case of both gene and protein in some manner ideal for angiogenic gene delivery [63, 68] . therapy approaches, delivery issues are critical to their However, this limited duration of expression is at least therapeutic effectiveness and these will be addressed later partially attributed to an immune response against in this review. adenoviral proteins [69, 70] and may be very short indeed in patients with pre-existing neutralizing antibodies. Thus, considerable concerns have risen over inflammatory responses to these vectors, although this remains contro-4. Efficacy of angiogenic growth factors in versial and inflammatory responses may be more likely in myocardial ischemia some tissues than others [71] .
The issue of immune and inflammatory responses to Although preclinical evidence of in vivo efficacy has viral antigens may be partially overcome with alternative been obtained for all of the major angiogenic growth viral vectors (e.g. AAV) [72] . However, these vectors may factors, studies of FGF-2 and VEGF-A are the most lead to longer-term transgene expression with the concomiextensive to date (see [76] for a detailed review). FGF-2 tant safety concerns associated with prolonged angiogenic belongs to the FGF family that currently numbers 22 stimulation. Thus the 'gene therapy paradox' is that 'safer' members [77] . These proteins are distinguished by their vectors result in potentially deleterious prolongation of pattern of expression and preference for different subclastherapeutic gene expression. To address this issue, vector ses of FGF receptor (FGF-R) isoforms (FGF-R1-R4), and systems capable of regulated therapeutic gene expression the presence of the leader sequence (absent in FGF-1 and are currently under development [72] .
2). The ability of FGF-2 to induce angiogenesis in mature The other drawback of the gene therapy approach is tissues was suggested by studies that documented siginconsistent level of expression achieved with the same nificantly higher vessel counts following intracoronary dose in different patients. This is partly attributable to injections of FGF-2 in the setting of acute coronary delivery issues (see below) and partly to variability in the thrombosis in dogs and pigs [78, 79] . These studies were presence and level of neutralizing antibodies. With regard followed by more detailed functional evaluation of therato the latter, a screen of a consecutive series of patients peutic efficacy of FGF-2 in chronic myocardial ischemia referred for PTCA and / or CABG demonstrated that over that employed the ameroid constrictor model. The place-70% possessed neutralizing antibodies to type 5 adenoment of the ameroid constrictor leads to gradual narrowing virus, which in 50% achieved very high titers [73] . of the instrumented artery, which occludes completely over The major limitation of the protein therapy approach is about 3 weeks. This gradual occlusion together with the formation of a limited amount of native collateral vessels toxicity have not been observed in recent clinical studies results in development of chronic myocardial ischemia [9] . accompanied by myocardial hibernation in the affected FGF-4 and FGF-5 have been evaluated for their ancoronary territory with only limited subendocardial infarcgiogenic potency in the form of gene (adenoviral) therapy tion [80, 81] [63] and for this reason will not be discussed further here. Continuous administration of FGF-2 in the ameroid dog model, either directly into the occluded coronary artery or into the left atrium, resulted in augmentation of coronary 5. Delivery techniques flow [82, 83] . Similar studies in pigs showed that sustained release perivascular administration or intrapericardial deGiven that the therapeutic approach to induction of livery of FGF-2 not only improved myocardial blood flow angiogenesis uses highly potent angiogenic growth factors in the ischemic myocardium, but also improved regional that may have grave side effects, a high drug target level left ventricular function in the ischemic zone [84] [85] [86] .
and low systemic exposure should be the ultimate goal. Interestingly, despite the relatively systemic nature of these With the rapid growth of newly emerging delivery techdeliveries, the angiogenic effect of FGF-2 was limited to nologies, a continuous evaluation and re-evaluation of the ischemic myocardium with no increase in the vessel growth factor delivery methodology is clearly warranted. number or changes in coronary blood flow noted in nonCurrently, four clinically applicable catheter-based methischemic areas of the heart. Similarly, a single intracoronods (intravenous, intracoronary, intramyocardial and transary injection of FGF-2, but not intravenous administration, endocardial intramyocardial delivery) and two surgical resulted in improved perfusion [87, 88] and function [89] .
methods (transepicardial intramyocardial and slow release Experience with FGF-1 to date is much more limited.
epicardial delivery) are being evaluated. Early studies using a native form of FGF-1 protein Since efficacy studies in large animals are expensive and delivered by several different modalities reported no time-consuming, a number of biodistribution studies with 125 angiogenic effect [90, 91] . The significance of the studies, I-FGF-2 has been performed to compare the efficiency however, is limited given the very short half-life of the of these delivery strategies (Fig. 1 ) [103] [104] [105] . The results native FGF-1 protein [74] . Sustained release perivascular may be more of less specific to FGF-2 since this growth administration of the S117 mutant of FGF-1 that results in factor has a 5-fold higher affinity for extracellular heparan marked prolongation of the protein half-life [74] improved sulfates than FGF-1 [106] , which in turn has a much higher regional flow and function in chronically ischemic pig affinity than VEGF-A [107] . Despite this relative FGF-2-myocardium [92] . FGF-1, like FGF-2, also provides specificity, these studies provide a valuable insight with protection against ischemia-reperfusion injury, but this regard to all heparin-binding growth factors. effect is more likely due to the vasodilatory effects of Single intravenous or intracoronary administration of FGF-1 rather than its angiogenic effect, since a non-FGF-2 leads to myocardial deposition of ,0.6 or 1.5%, mitogenic FGF-1 mutant provided similar protection [93] .
respectively, of the total injected dose in the ischemic VEGF-A comes in at least five splicing forms as myocardium 1 h after administration [104] . Recovery from VEGF , VEGF , VEGF , VEGF and VEGF . In the normal myocardium is even less. Twenty-four hours   121  145  165  189  206 addition, there are currently four other closely related after administration, retention in the myocardium drops to genes termed VEGF-B, -C, -D and -E [13] . Of these, ,0.1% of the initial amount administered. With in-VEGF-A has been studied most extensively in the trapericardial deposition of FGF-2, ,1% is recovered from 165 cardiovascular system. In animal models of chronic the myocardium at 1 h but retention at 24 h is slightly myocardial ischemia, VEGF improved collateral blood better, with 0.5% in the normal myocardium and up to 8% 165 flow [47, 94] . Sustained perivascular administration, but (with a very high variability), in the ischemic myocardium also single bolus intracoronary injection of VEGF [104] . 165 proved to be sufficient to improve myocardial flow and Transendocardial or transepicardial injections compare function in the pig ameroid model [95] . Similar to FGF-2, favorably, with 25-30% of the injectate being recovered single intravenous [89] or repetitive intra-atrial injection of from the myocardium and 5% retained up to 3 days after VEGF were not effective [96] . Long-term side effects, such as induction of tumor all these cases, most of the I FGF-2 activity was growth or exacerbation of proliferative retinopathy [97] , recoverable from the liver and the lungs. It is unknown atherosclerosis [98] or bone or kidney disorders [99] , did whether the low recovery and short retention has funcnot occur in these small-scale efficacy studies. However, tional consequences or whether the amount retained by the systemic hypotension proved to be a dose limiting side target tissue is still sufficient to exert a physiological effect of both VEGF [100, 101] and FGF-2 [102] although effect. For instance, when 200 mg of FGF-2 is given doses of FGF-2 leading to significant hypotension are intracoronary, 200 ng (0.1%) is retained up to 24 h in the substantially higher than for VEGF-A. Furthermore, other ischemic myocardium. With a flow area of one coronary side effects of FGF-2, including proteinuria and CNS artery taken as 150 g of tissue and a 33% (50 ml) specialized equipment and a higher skill level of the operator than needed for intracoronary injection [109] . Furthermore, if the ultimate goal of therapy is to induce arteriogenesis of the epicardial vessels, intramyocardial injection may not prove to be the most logical or ideal place of growth factor delivery. In this regard it should be noted that to date no conclusive data regarding physiological efficacy of this mode of administration has been presented. Intrapericardial administration, despite its theoretical appeal, is limited due to very high (.90%) frequency of prior coronary artery bypass surgery in patients currently enrolling in angiogenesis trials [61] and by high operator skill level required for access of the normal pericardial space.
Taking all the evidence into account animal studies suggest that protein therapy can be effective with single administration if delivered through the intracoronary or pericardial route. This puts protein-based therapeutic angiogenesis into the realm of clinical feasibility in a wide range of patients.
Clinical trials of protein therapeutics
Therapeutic angiogenesis for treatment of ischemic cardiac disease is still in its infancy and to date, no phase III trials have been initiated with protein-based therapy in these patients. However, limited efficacy data were derived from ongoing and completed phase I / II trials.
Safety of FGF-1 (10 mg / kg) was first demonstrated in compared to control patients, there was no other evidence of improved coronary perfusion or ventricular function. Seeking to address these issues, we performed a doubleestimated extracellular distribution phase, the concentrablind randomized trial of epicardially implanted FGF-2 tion of FGF-2 will be in the order of 4 ng / ml, which is still protein in a sustained release (heparin-alginate) beads. in the range of the effective concentrations used for in Twenty-four patients undergoing CABG in whom one of vitro studies [108] . With the possibility of occluded or the major arteries was not viable but ischemic myocardium partially occluded epicardial coronary arteries, FGF-2 was considered not bypassable for technical reasons, were distribution will be much more heterogeneous and lower in randomized to receive ten heparin-alginate beads with a non-perfused area. With direct intramyocardial injection total dose of 10 or 100 mg FGF-2 or a placebo [8] . Nuclear with 10 mg injected per each injection site and a 5%
and MRI perfusion scans were performed prior to hospital retention, 500 ng will be retained by |10 cc of tissue discharge and then again at 90 days. Two patients in the yielding an effective local concentration of 50 ng / ml. trial died at the time of CABG (one in the control, and one From these studies, it may be concluded that intramyocarin the 100-mg FGF-2 group). At the time of the 90-day dial delivery of growth factors is preferred since it includes evaluation, all seven remaining patients in the 100 mg the possibility of targeting the desired areas of the heart, FGF-2 group were symptom-free while three of seven and has a higher efficiency of delivery and prolonged patients in the control group continued to experience tissue retention.
angina and two required additional revascularization proThis enthusiasm for the intramyocardial administration cedures. Both nuclear and MR perfusion imaging demonis tempered by its invasive nature, a requirement for highly strated a significant reduction in the size of the target zone in the 100-mg FGF-2 group but not in the 10-mg FGF-2 or factor therapy as well as a first demonstration of symptomcontrol groups. Thus, this small study demonstrated the atic improvement in a double-blind, placebo-controlled safety and feasibility of this mode of FGF-2 therapy.
format. Another important lesson is the extent and prevalThe safety and feasibility of intracoronary and intravenence of the placebo effect in this patient population. In ous FGF-2 delivery was tested in an open-label dosefact, this placebo response clearly makes evaluation of escalation Phase I study of 66 patients with severe efficacy possible only in the double-blind trial format. coronary disease that were suboptimal candidates for Additionally, this trial demonstrated relative safety of conventional therapeutic approaches [9] . Fifty-two patients intracoronary FGF-2 in a considerable number of high risk received intracoronary infusions of FGF-2 ranging in dose patients. In particular, there was no excess mortality or from 0.33 to 48 mg / kg and fourteen patients received sudden death in FGF-2 treated patients and this mortality intravenous infusions of 24 and 36 mg / kg FGF-2. FGF-2 (2%) was significantly lower then seen in laser revasculariinfusions were well tolerated with systemic hypotension zation trials [111, 112] . becoming the dose-limiting toxicity at 48 mg / kg. Clinical
The prevalence of the placebo response and the dangers follow-up over 6 months documented mortality in four of open label analysis were amply demonstrated in clinical patients (two sudden deaths in patients with 22% and 30% trials of intracoronary and intravenous VEGF-A . Two 165 EF, one death following a cardiac transplant and one from small Phase I trials of intracoronary (n516) and intraventhe non-Hodgkin's lymphoma diagnosed 8 days after FGFous (n514) VEGF infusions were interpreted to show a 2 infusion) while no significant laboratory toxicity was significant improvement in exercise capacity, symptoms observed. Angina frequency score and exertional capacity (defined as angina class) as well as promising results with score were improved in the entire FGF-2 patient popula-SPECT imaging [113, 114] . However, a randomized, doubtion at 2 and 6 months compared to the baseline. Furtherle-blind, placebo-controlled Phase II trial (VIVA trial) of more, the FGF-2 patients as a group demonstrated a two different dosages of VEGF was completely negative 2.4-min improvement in the treadmill exercise time while with regard to exercise time, symptom improvement and MRI perfusion imaging demonstrated a significant reducnuclear imaging [115] . Several unusual features of this tion in the size of the ischemic territory and improved left trial make interpretation of therapeutic efficacy of VEGFventricular wall thickening in this territory. Taken together, A somewhat problematic. In particular, the format for 165 these results suggest that intracoronary infusions of FGF-2 VEGF delivery -an intracoronary infusion followed by are reasonably safe and may produce functionally signifithree intravenous infusion given over the next 7 days was cant benefits.
never tested in either animal models or Phase I trials. These claims were tested in a 337-patient double-blind Given that VEGF is not effective when delivered intravenphase II trial that examined three different intracoronary ously [116] and that repeat administrations of VEGF dosages of FGF-2 (0.3, 3 and 30 mg / kg) versus placebo induce VEGF receptor tachyphylaxis [101] , the regimen is controls (FIRST trial). Ninety-day follow-up data demonclearly suboptimal and may even be counterproductive. strated a non-significant improvement in the treadmill time Furthermore, the highest VEGF dose tested in the trial, 50 in FGF-2 treated patients (P50.22 for the 3.0 mg / kg ng / kg / min, was not found to be effective in the porcine group). At the same time, there was a significant improveameroid model study [116] . Finally, the VIVA trial enrolled ment in the Canadian Cardiovascular Society (CCS) a high proportion of patients with Class II angina that in angina scale (P50.01 for the 3.0 mg / kg group) and Seattle the light of the FIRST trial data, are unlikely to benefit Angina Questionnaire (SAQ) angina frequency scale. from angiogenic therapy. Nuclear imaging demonstrated no overall improvement in the size of ischemic territories although patients with ischemia on the rest nuclear imaging study (thus demonstrated the presence of hibernating myocardium) demon- shown efficacy in animal models of hindlimb ischemia, the study suggested that the benefit, defined as improvemost clinical attention has focused on gene therapy [120] . ment in symptoms, exercise time and reduction in the size Therefore, clinical information on protein-based growth of nuclear-imaging determined ischemic zone defect, was factor therapy in this field is rather scarce. A small Phase I most prominent in 'sicker' patients as defined by lower study of intra-arterial FGF-2 suggested improvement with baseline exercise capacity, higher baseline symptom freregard to lower limb perfusion in the treated patients quency and larger nuclear perfusion defects. The validity [Lazarous et al., unpublished] . This claim is being tested in of these concepts, however, will require further testing in a a currently ongoing double-blind placebo controlled double-blind study format.
TRAFFIC study that is evaluating single or double (30 day The importance of this trial lies in the first delineation of apart) intra-arterial infusions of FGF-2 in patients with patient subsets likely to positively respond to the growth claudication.
Future issues 9. Summary and conclusions
The first and foremost task in cardiovascular therapeutic The development of angiogenic growth factor therapy angiogenesis, whether by protein or gene therapy, is to has potentially added new therapeutic alternatives for show the clinical efficacy of a combination of growth patients debilitated by serious cardiovascular diseases. factor and delivery strategy in randomized double blind, While initial results are clearly exciting, we have yet to placebo-controlled trials. Current clinical experience in prove its clinical efficacy in the absence of serious toxicity CAD trials suggest that three issues appear critical to and side effects. At the moment, protein-based therapy successful evaluation of this mode of therapy: effective seems to have advantages over gene therapy, although delivery, proper selection of patients and the choice and continuous efforts should be made to increase tissue timing of outcome measures [61] . The delivery-related exposure time after a single administration of protein. issues have already been addressed in this review. The Finally, double-blind, placebo-controlled trials designed choice of patients for these trials is critical, and must take with existing animal data as a guideline, are needed to into account the initial variability among patients due to firmly establish therapeutic angiogenesis or arteriogenesis disease severity, previous treatments like angioplasty and in cardiovascular disease. bypass surgery and ongoing atherogenesis. Apparently, more severely diseased patients respond better to angiogenic treatment than less sick patients. In the FIRST Acknowledgements trial patients with baseline SAQ angina frequency score .40 not only showed no response to FGF-2 administration Supported in part by NIH grants HL53793, 56993, with regard to their symptom frequency, but also did not 63609 and RR01032. Dr. Simons is an Established Invesshow a placebo response in the control group that was so tigator of the American Heart Association. prominent among patients with a baseline SAQ angina score ,40. Finally, the choice of outcome measures and their timing are major challenges. For regulatory purposes, References demonstration of clinical benefit, an improvement in life expectancy, some life-quality related benefit such as life end-points may currently be the best choice in this teriogenesis is likely to take several weeks. The VIVA trial tinues at least until 6 months after treatment [115] . A first clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645-650.
6-month follow-up of the FIRST trial will provide im- In the meantime, parallel animal and clinical studies will coronary artery disease using direct intramyocardial administration
